LXLianbo Xiao

Lianbo Xiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lianbo Xiao has a total of 230 co-authors. Here are the top co-authors by number of shared publications:

  • Jun Xie

    Department of Orthopedics, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

    21 shared publications
  • Jun Shen

    Guanghua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    19 shared publications
  • Sheng Zhong

    Department of Orthopedics, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

    18 shared publications
  • Xirui Xu

    Guanghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    16 shared publications
  • Chi Zhao

    School of Acupuncture-Moxibustion and Tuina, Henan University of Chinese Medicine, Zhengzhou, China

    14 shared publications
  • Hui Xu

    School of Acupuncture-Moxibustion and Tuina, Henan University of Chinese Medicine, Zhengzhou, China

    14 shared publications

Latest Publications

  • Open Access

    Juanbi Qianggu Formula Alleviates Rheumatoid Arthritis by Suppressing the TNF-α/NF-κB Signaling Pathway

    by Guowei Qiu, Junjie Wen, Zheng Xiang, Wei Hu, Xinyu A, Chenxin Gao, Yanqing Bian, Xirui Xu, Lu Meng, Lianbo Xiao

  • BCAT2 links branched-chain amino acids metabolism to interferon signaling to sustain macrophage inflammation

    by Xiaohui Meng, Haihui Han, Wulin You, Pengfei Xin, Ya Ju, Liangyu Cai, Lamei Zhou, Sheng Zhong, Zhuoyi Hu, Zhiyu Chen, et al.


  • Open Access

    FGF/FGFR signaling at the immune-stromal interface in autoimmune rheumatic diseases: from tissue remodeling to translational opportunities

    by Sheng Zhong, Xiaohui Meng, Zheng Xiang, Guowei Qiu, Songtao Sun, Jun Xie, Lianbo Xiao

    The fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling system regulates tissue repair, angiogenesis, extracellular matrix remodeling, fibrosis, and bone metabolism. Although FGF/FGFR biology has been extensively studied in oncology, development, and fibrotic lung disease, its relevance to systemic autoimmune rheumatic diseases remains scattered across disease-specific and unevenly supported literatures. This narrative, evidence-informed review synthesizes current evidence on FGF/FGFR signaling in rheumatoid arthritis (RA), systemic lupus erythematosus/lupus nephritis (SLE/LN), systemic sclerosis (SSc), spondyloarthritis/psoriatic arthritis (SpA/PsA), and Sjögren’s disease. We explicitly distinguish mechanistically supported axes from biomarker-level associations and extrapolated regenerative concepts. In RA, FGF10/FGFR1 and FGF2/FGFR3 have the strongest tissue-level support, linking relapse-prone synovial fibroblast niches, fibroblast-like synoviocyte activation, angiogenesis, and bone erosion. In SLE/LN, FGF23/Klotho is best interpreted as an emerging renal-metabolic and inflammatory biomarker axis rather than a validated therapeutic target, although reported associations with urinary MCP-1/CCL2 suggest testable links to renal chemokine-mediated inflammation. In SSc-ILD, nintedanib demonstrates that FGFR-containing multi-kinase networks are clinically tractable, but the FGFR-specific contribution remains unresolved. In SpA/PsA, FGF2-mediated angiogenesis-osteogenesis coupling and FGF7/FGFR2IIIb signaling provide candidate mechanisms for entheseal remodeling, whereas direct human entheseal validation is still lacking. In Sjögren’s disease, FGF7/FGF10/FGFR2b signaling supports a regenerative hypothesis derived mainly from salivary gland developmental biology and organoid studies. We propose an axis-prioritization translational framework that specifies ligand-receptor pairs, patient subgroups, validation tissues, delivery strategies, pharmacodynamic endpoints, and clinical or imaging readouts. This review is not a systematic review or meta-analysis; rather, it provides a structured roadmap for tissue-level validation, longitudinal biomarker studies, and short-course proof-of-mechanism trials before clinical translation.


  • Open Access

    Cellular crosstalk and signaling networks in the rheumatoid arthritis synovial microenvironment

    by Maozhi Feng, Hongtai Chen, Lu Liao, Donghong Huang, Jun Shen, Lianbo Xiao, Qigui Lu, Pingjin Xie

    Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation, pannus formation, and progressive cartilage and bone destruction. Within the RA synovial microenvironment, resident synoviocytes, mesenchymal stem cells, fibroblasts, adipocytes, vascular-associated cells, and diverse immune cell populations form a dynamic interaction network through direct contact and paracrine mediators, including cytokines, chemokines, complement components, and extracellular vesicles. This review summarizes how these cellular interactions drive RA along a pathological continuum from early autoimmune initiation, through middle-stage inflammatory amplification and synovial hyperplasia, to late fibrosis, pannus formation, dysregulated bone remodeling, and irreversible structural damage. Particular emphasis is placed on the dynamic balance between pathogenic cellular circuits and immunoregulatory programs within the synovial microenvironment, which helps determine whether the joint remains in an inflammatory-active state, re-enters a remission-associated and relatively rebalanced state, or progresses toward remission failure and structural injury. We further discuss the major signaling pathways that mediate these interactions, especially NF-κB, MAPK, JAK-STAT, TGF-β/Smad, and Wnt/β-catenin signaling, highlighting how pathway crosstalk contributes to inflammatory persistence, loss of tissue plasticity, and progressive remodeling. Importantly, because key cellular subsets and interaction programs may still retain partial plasticity during the early and middle stages of disease, stage-adapted modulation of these pathogenic networks may help restore synovial immune homeostasis, promote remission, delay disease progression, and reduce irreversible tissue damage. A deeper understanding of stage-specific cellular programs and interaction networks may therefore provide a stronger theoretical basis for mechanism-informed precision therapies in RA.


  • Open Access

    Correction: Targeting lactate metabolism to restore immune homeostasis: a precision therapeutic paradigm for rheumatoid arthritis

    by Lin Zheng, Xinyu A, Shiyu Ma, Bo Xu, Zheng Xiang, Boran Cao, Jun Shen, Xirui Xu, Yiwei Cheng, Lei Ran, et al.

  • Open Access

    Plasma Proteomics Identifies Thousand‐and‐One–Amino Acid Kinase 3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

    by Pengfei Xin, Wenzhen Li, Xinyu A, Jun Shen, Xiaohui Meng, Yanqin Bian, Haihui Han, Zheng Xiang, Lei Ran, Songtao Sun, et al.

    Objective: Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted therapy. Methods: Data‐independent acquisition mass spectrometry was used for proteomic quantification and bioinformatic analysis on plasma samples from 160 patients with RA and 40 healthy controls. Key proteins associated with bone destruction were screened by integrating Sharp scores with synovial single‐cell RNA sequencing data and subsequently validated in two independent cohorts (N 1 = 50 and N 2 = 10) using enzyme‐linked immunosorbent assay and multiplex immunohistochemistry. Functional studies were conducted using fibroblast‐like synoviocytes (FLSs) in vitro and a collagen‐induced arthritis (CIA) mouse model in vivo. Results: A total of 4,998 plasma proteins were identified, with 506 showing significant differential expression between active and remitted RA. Thousand‐and‐one–amino acid kinase 3 (TAOK3) levels were positively associated with Sharp scores and markedly elevated in patients with active RA. Combining TAOK3 with C‐reactive protein improved diagnostic accuracy for active RA (area under the curve = 0.915). High TAOK3 expression was also associated with increased relapse frequency. Functional studies showed that TAOK3 knockdown suppressed the tumor‐like phenotype of FLSs and down‐regulated matrix metalloproteinase 1/2/3 and cathepsin K, whereas TAOK3 overexpression promoted pannus cell–mediated bone erosion, mitigated by TAOK3‐targeted inhibitor. In vivo, its inhibition showed therapeutic effects in CIA mice. Conclusion: TAOK3 serves as a potential biomarker for bone destruction in active RA and as a therapeutic target for precision monitoring and intervention.


  • Open Access

    Correction: Targeting lactate metabolism to restore immune homeostasis: a precision therapeutic paradigm for rheumatoid arthritis

    by Lin Zheng, Xinyu A, Shiyu Ma, Bo Xu, Zheng Xiang, Boran Cao, Jun Shen, Xirui Xu, Yiwei Cheng, Lei Ran, et al.

  • Open Access

    Correction: Integrative multi-omics analyses identify PKD1 and SLC2A4 as genetically supported glycolysis-related candidate genes for rheumatoid arthritis

    by Xinyu A, Pengfei Xin, Lin Zheng, Bo Xu, Jianye Wang, Songtao Sun, Jun Xie, Chenxin Gao, Peijun Pan, Guowei Qiu, et al.

  • Open Access

    Comparison of clinical application of locking plate versus cancellous screw in structural autologous bone grafting during TKA for medial tibial bone defects

    by Nanshan Ma, Yiwei Cheng, Haoyuan Ding, Dapeng Han, Sheng Zhong, Jun Xie, Qing Xia, Jing Zhang, Pengfei Xin, Lianbo Xiao

    Objective: To compare the clinical outcomes of locking plate versus cancellous screw fixation in structural autologous bone grafting for medial tibial bone defects during total knee arthroplasty. Methods: A retrospective analysis was conducted on 66 patients with medial tibial bone defects who underwent TKA between January 2024 and December 2024. Among them, 34 patients received locking plate fixation (LP group), and 32 patients received cancellous screw fixation (CS group). Postoperative outcomes, including the hip–knee–ankle (HKA), Knee Society Score (KSS) and postoperative complications were recorded and compared to evaluate graft integration and functional recovery. Results: All patients successfully completed the surgery. At the final follow-up, both groups showed significant improvement in HKA angle, KSS Knee Score, and KSS Function Score compared to preoperative values (P < 0.05). However, no statistically significant differences were observed between the two groups at any time point in terms of KSS Knee and Function Scores (P > 0.05). No postoperative complications occurred in either group during the follow-up period. Conclusion: Compared with conventional cancellous screw fixation, the use of locking plate combined with structural autologous bone grafting provides similarly favorable clinical outcomes. Furthermore, locking plate offer broader intraoperative applicability and may serve as an effective internal fixation strategy for managing medial tibial bone defects during TKA.

  • Open Access

    Integrative multi-omics analyses identify PKD1 and SLC2A4 as genetically supported glycolysis-related candidate genes for rheumatoid arthritis

    by Xinyu A, Pengfei Xin, Lin Zheng, Bo Xu, Jianye Wang, Songtao Sun, Jun Xie, Chenxin Gao, Peijun Pan, Guowei Qiu, et al.

    Introduction: Glycolytic reprogramming has been implicated in rheumatoid arthritis (RA) pathogenesis, yet the underlying causal genes and epigenetic mechanisms remain unclear. This study aimed to systematically identify glycolysis-related genes and their methylation-regulated expression that may causally influence RA susceptibility. Methods: We conducted a multi-omics Mendelian randomization (MR) analysis integrating genome-wide association study (GWAS) summary statistics for RA (FinnGen, UK Biobank, GCST90129453) with quantitative trait loci (QTLs) for blood-derived methylation (mQTL), expression (eQTL), and protein abundance (pQTL). Summary-data-based Mendelian randomization (SMR) and colocalization analyses were used to identify causal molecular signatures linking DNA methylation, gene expression, and protein abundance with RA risk. Replication was performed in independent RA cohorts. In addition, qPCR validation was conducted in an independent whole-blood cohort (30 RA patients and 30 healthy controls). Results: SMR identified 129 CpG sites (75 genes), 28 transcripts, and 9 proteins significantly associated with RA risk. Seven glycolytic genes—PKD1, SLC2A4, ALAS1, ALDH7A1, LRFN3, PFKFB2, and PYGB—showed consistent evidence across methylation, expression, and GWAS datasets. Notably, hypomethylation at cg07036112 (PKD1; OR = 0.68, 95% CI: 0.59–0.78) and cg06891043 (SLC2A4; OR = 0.92, 95% CI: 0.89–0.96) was associated with increased gene expression and increased RA susceptibility. Colocalization supported shared causal variants at these loci (PP.H4 > 0.5). Additional signals included cg13241645 (ALAS1; OR = 0.72, 95% CI: 0.65–0.80) and cg01380361 (PFKFB2; OR = 1.33, 95% CI: 1.17–1.51). qPCR confirmed increased PKD1 and SLC2A4 mRNA expression in RA compared with healthy controls. Discussion: This integrative multi-omics MR framework supports an epigenetically mediated contribution of glycolysis-related regulation to RA susceptibility and nominates PKD1 and SLC2A4 as robust genetically supported candidate genes. These findings highlight methylation-linked transcriptional changes in glycolysis-related pathways implicated in RA and suggest potential biomarkers and therapeutic targets.